Genmab A/S FY2025 EPS Forecast Lifted by Leerink Partnrs

Genmab A/S (NASDAQ:GMAB - Free Report) - Equities researchers at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued on Thursday, May 8th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $1.68 per share for the year, up from their prior forecast of $1.59. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S's Q4 2025 earnings at $0.62 EPS and FY2026 earnings at $1.98 EPS.

GMAB has been the subject of several other research reports. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a report on Thursday, February 13th. Finally, Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Trading Up 0.3%

GMAB stock traded up $0.06 during midday trading on Monday, hitting $19.71. The company had a trading volume of 284,376 shares, compared to its average volume of 1,104,958. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.06. The stock's 50 day moving average price is $19.75 and its 200 day moving average price is $20.79. The stock has a market cap of $12.63 billion, a price-to-earnings ratio of 11.34, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after acquiring an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after acquiring an additional 1,070 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.